Vectus Biosystems Hits Inflection Point: 60% Share Spike When Licensing Kidney-Fibrosis Drug to XORTX Therapeutics
Vectus Biosystems (ASX: VBS) surged 60% following a strong quarterly update, driven by a major…
11
Stocks in Spotlight
View all →-
Financials · Growth Stocks Powerhouse Ventures (ASX:PVL) Builds a Merchant Revenue Engine as CIO Fund Scales July 3, 2026 -
Financials · Growth Stocks Powerhouse Ventures (ASX:PVL) US$50m Partner Commitment Puts CIO Fund Re-Rate in Focus June 26, 2026 -
Growth Stocks WiseTech Global (ASX:WTC) Why the A$30 Sell-Off Could Be a Long-Term Opportunity June 23, 2026
